TearClear announced it has raised $22 million in a Series B funding round. The company intends to use the funds to advance multiple clinical programs in development, with two lead candidates in glaucoma paving the way for future indications.
Led by Chief Executive Officer Robert Dempsey, TearClear is an ophthalmic pharmaceutical company advancing two lead product candidates in glaucoma.
Backers included Visionary Ventures, Bluestem Capital and Flying L Partners, who collaborated with Falcon Vision, a platform formed by KKR to advance innovation in ophthalmology.
The company also announced the appointment of Stuart Raetzman, who most recently served as Chief Executive Officer of Galderma, to the TearClear Board of Directors.